Jenny Treece, PHARMD in Fairfield, AR - Pharmacist

Jenny Treece, PHARMD is a Pharmacist based in Fairfield, Arkansas. Jenny Treece is licensed to practice in Arkansas (license number PD10105) and her current practice location is 367 Dave Creek Parkway, Fairfield, Arkansas. She can be reached at her office (for appointments etc.) via phone at (501) 884-3388.

NPI number for Jenny Treece is 1033758420 and her current mailing address is Po Box 1223, Fairfield, Arkansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1033758420.

Contact Information

	Jenny Treece, PHARMD
	367 Dave Creek Parkway, Fairfield, AR 72088-1223
	(501) 884-3388
	(501) 884-3301

Healthcare Provider's Profile

Full Name	Jenny Treece
Gender	Female
Speciality	Pharmacist
Location	367 Dave Creek Parkway, Fairfield, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1033758420
Provider Enumeration Date: 01/02/2020
Last Update Date: 01/02/2020

Medical Identifiers

Medical identifiers for Jenny Treece such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1033758420	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	PD10105 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jenny Treece is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jenny Treece, PHARMD Po Box 1223, Fairfield, AR 72088-1223 Ph: (501) 884-3388	Jenny Treece, PHARMD 367 Dave Creek Parkway, Fairfield, AR 72088-1223 Ph: (501) 884-3388

News Archive

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Mindfulness training can influence preschoolers' self-regulation and food liking

Mindfulness training and engaging in classroom-based games can influence self-regulation and food liking when introduced during the preschool years according to a new study in the Journal of Nutrition Education and Behavior, published by Elsevier.

Florida senators introduce bill to prevent Medicaid fraud

Florida Senate Health Regulation Committee Chair Don Gaetz (R) and state Senate Health and Human Services Appropriations Committee Chair Durell Peaden (R) at a news conference on Wednesday "expressed confidence" that lawmakers will pass legislation (SB 1986) aiming to prevent and detect Medicaid fraud, the Tallahassee Democrat reports.

UNAIDS, UNDP, WHO release policy brief advising countries on using TRIPS flexibilities to drive down HIV treatment costs

Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

Jenny Treece, PHARMD - Pharmacist in Fairfield, AR